Dr Andrew N Stephens completed his PhD at Monash University prior to holding postdoctoral positions at the University of Sydney and Prince Henry’s Institute.  In 2009, he established the Ovarian Cancer Biomarkers group, to specifically drive new research into the design and development of diagnostic tools, and to improve the detection and management of ovarian cancers.

Dr Stephens is passionate about reducing mortality from ovarian cancer, and has developed a strong and comprehensive research portfolio. Together with his team, he has published extensively and holds several patents detailing new diagnostic and therapeutic technologies for ovarian cancer management. A public advocate for ovarian cancer research and long-standing Fellow of the Ovarian Cancer Research Foundation, he is committed to translating research into practice.

Selected publications

  • Moffitt LR, Karimnia N, Stephens A, Bilandzic M (2019) Therapeutic Targeting of Collective Invasion in Ovarian Cancer. Int J Mol Sci doi: 10.3390/ijms20061466.

  • Leung D, Rainczuk A, Nguyen T, Stephens AN, Silke J, Fuller P, Chu S (2019). Targeting XIAP and PPARγ in granulosa cell tumors alters metabolic signaling. J Proteome Res 18:1691-1702.

  • Wilson AL, Wilson KL, Bilandzic M, Moffitt LR, Makanji M, Gorrell MD, Oehler MK, Rainczuk A, Stephens AN, Plebanski M (2018). Non-invasive fluorescent monitoring in an immunocompetent mouse model of ovarian cancer. Cancers (Basel) doi: 10.3390/cancers11010032.

  • Gao Q, Xiang SD, Wilson K, Madondo M, Stephens AN, Plebanski M (2018). Sperm protein 17 expression by murine epithelial ovarian cancer cells and impact on tumor progression. Cancers (Basel) doi: 10.3390/cancers10080276.

  • Sandow JJ, Rainczuk A, Infusini G, Makanji M, Bilandzic M, Wilson AL, Fairweather N, Stanton PG, Garama D, Gough D, Jobling TW, Webb AI, Stephens AN (2018) Discovery and validation of novel protein biomarkers in ovarian cancer patient urine. Proteomics Clin Appl 12:e1700135.

  • Wilson AL, Moffitt LR, Duffield N, Rainczuk A, Jobling TW, Plebanski M, Stephens AN (2018) Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-stage, High Grade Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 27:183-192.

  • Kampan NC, Xiang SD, McNally OM, Stephens AN, Quinn MA, Plebanski M (2018) Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: Challenges and opportunities. Curr Med Chem 25:4785-4806.

  • Wilson AW, Plebanski M, Stephens AN (2018). New trends in anti-cancer therapy: Combining conventional chemotherapeutics with novel immunomodulators. Curr Med Chem 25:4758-4784.

  • Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M (2017) Interleukin 6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor receptor 2-expressing regulatory T cells. Front Immunol 8:1482.

  • Heng S, Stephens AN, Jobling TW, Nie G (2016) Total PC activity is increased in uterine lavage of post-menopausal endometrial but not ovarian cancer patients. J Cancer 7:1812-1814.

  • Heng S, Stephens AN, Jobling TW, Nie G (2016) Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget 7:46573-46578.

  • Stanton PG, Foo CF, Rainczuk A, Stephens AN, Condina M, O’Donnell L, Weidner W, Ishikawa T, Cruickshanks L, Smith LB, McLachlan RI (2016) Mapping the testicular interstitial fluid proteome from normal rats. Proteomics 16:2391-2402.

  • Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD, Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG (2015) Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6:37663-37677.

  • Zhang H, Maqsudi S, Rainczuk A, Duffield N, Lawrence J, Keane FM, Justa-Schuch D, Geiss-Friedlander R, Gorrell MD, Stephens AN (2015) Identification of Novel Dipeptidyl Peptidase 9 Substrates by Two-Dimensional Differential In-Gel Electrophoresis. FEBS J 282:3737-3757.

  • Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD, Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL (2015) Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med 7:87.